Tuesday, November 13, 2018

Sofosbuvir/ledipasvir cures most young children with hepatitis C

Sofosbuvir/ledipasvir cures most young children with hepatitis C
Liz Highleyman 
Published: 13 November 2018
Almost all young children ages 3 to 6 years with chronic hepatitis C achieved sustained virological response after 12 weeks of treatment using sofosbuvir/ledipasvir oral granules, according to findings presented at the 2018 AASLD Liver Meeting in San Francisco.

The prevalence of hepatitis C virus (HCV) infection is low among children in Europe and the US, though there is concern that the rate may be rising in the US as more young women become infected as a consequence of the burgeoning opioid epidemic. In some resource-limited countries such as Egypt, HCV among children is much more common.

The advent of direct-acting antiviral agents (DAAs) has revolutionised the treatment of hepatitis C for adults. These include Gilead Science's HCV polymerase inhibitor sofosbuvir (marketed alone as Sovaldi) and NS5A inhibitor ledipasvir, which are co-formulated in a 400/90mg once-daily tablet (Harvoni). 

Twitter - @infohep

On Twitter 
Full-text article downloaded & shared via twitter by Henry E. Chang:
Safety & efficacy of LDV-SOF with or without RBV for chronic hepatitis C in children ages 6-11.

No comments:

Post a Comment